The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes
Annals of Vascular Surgery · 2026-09 · 130 · 282-289
DOI: 10.1016/j.avsg.2026.04.044 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Vascular Surgery, 2026-09. Verfasst von Judith A H M Peeters und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands. Hauptthemen laut MEDLINE: Bone Marrow Transplantation, Ischemia, Early Termination of Clinical Trials, Peripheral Arterial Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: To evaluate the efficacy and safety of REX-001, an autologous bone marrow-derived mononuclear cell product, in patients with chronic limb-threatening ischemia (CLTI) who had no options for revascularization. METHODS: In this multicenter, double-blind, randomized, placebo-controlled phase III clinical trial, diabetic patients with CLTI (Rutherford category 5), no revascularization options, and no urgent need for amputation were enrolled. Bone marrow (250 mL) was processed to create REX-001, and a single intra-arterial injection was administered. Primary endpoints included change in Rutherford classification (to category 4 or lower) or complete ulcer healing within 12 months. Secondary endpoints included limb TcpO2, ulcer size, quality of life, ankle-brachial index, 6-min walking test, and amputation-free survival. RESULTS: The trial was stopped early after an interim analysis of 50% of the patients due to lack of efficacy. Thirty-two patients completed the study (21 REX-001, 11 placebo). Complete ulcer healing or improvement in Rutherford category occurred in 28.6% of REX-001-treated patients and 27.3% of placebo-treated patients. No treatment-related adverse events or safety concerns were identified. Data on secondary endpoints were not available. CONCLUSION: This prematurely ended study failed to confirm REX-001's efficacy for ulcer healing. Nevertheless, the study provides valuable insights into trial design, endpoint selection, and data stewardship, guiding future regenerative therapy research in this challenging patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Vascular Surgery, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
- Department of Vascular Surgery, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands. Electronic address: A.Schepers@lumc.nl.
Zitieren
APA
Peeters, J. A. H. M., Hamming, J. F., Quax, P. H. A., & Schepers, A. (2026). The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes. Annals of Vascular Surgery, 130, 282-289. https://doi.org/10.1016/j.avsg.2026.04.044
Vancouver
Peeters JAHM, Hamming JF, Quax PHA, Schepers A. The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes. Annals of Vascular Surgery. 2026;130:282-289. doi:10.1016/j.avsg.2026.04.044
BibTeX
@article{Peeters2026,
author = {Peeters, Judith A H M and Hamming, Jaap F and Quax, Paul H A and Schepers, Abbey},
title = {The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes},
journal = {Annals of Vascular Surgery},
year = {2026},
volume = {130},
pages = {282--289},
doi = {10.1016/j.avsg.2026.04.044}
}
EUVIMED